secwatch.observer — SEC 8-K summary
======================================

Issuer:     XOMA Royalty Corp (XOMA)
CIK:        0000791908
Form:       8-K
Filed at:   2024-02-16T23:59:59+00:00
Accession:  0001193125-24-038129
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

XOMA to acquire Kinnate Biopharma for up to $2.5879 per share plus CVR
----------------------------------------------------------------------

- Cash consideration of $2.3352 base plus up to $0.2527 additional per share; plus CVR for 85% or 100% of program sale proceeds.
- Kinnate must have at least $120M net cash at closing; expected close in April 2024.
- XOMA expects to add ~$9.5M cash to balance sheet and acquire early-stage oncology programs.
- Support agreements covering ~46% of Kinnate shares signed; Kinnate board unanimously approved.
- Tender offer to commence by March 4, 2024; financing condition waived.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/791908/000119312524038129/0001193125-24-038129-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/791908/000119312524038129/d793007d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-038129

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer